Antisense and RNAi Therapeutics Market to Soar USD 30.03 Bn by 2033

Antisense and RNAi Therapeutics Market Size and Growth Report 2023 - 2033

The global antisense and RNAi therapeutics market was estimated at US$ 5.20 billion in 2023 and is projected to grow to US$ 30.03 billion by 2033, rising at a compound annual growth rate (CAGR) of 19.12% from 2024 to 2033. Funding for research and development of rare diseases is promoting the market’s growth.

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways: North America Tops; RNAi & Genetic Disorders Rise

• By region, North America dominated the market by 62.10% in 2023.
• By region, Asia Pacific is expected to grow at the fastest rate during the forecast period.
• By technology, the antisense RNA segment held the largest share of the market in 2023.
• By technology, the RNA interference segment is anticipated to grow at the fastest rate during the forecast period.
• By application, the neurodegenerative disorders segment dominated the antisense and RNAi therapeutics market in 2023.
• By application, the genetic disorders segment is expected to grow with the fastest CAGR during the forecast period.
• By route of administration, the intrathecal injections segment held the largest share of the market in 2023.
• By route of administration, the subcutaneous injection segment is estimated to grow at the fastest rate during 2024-2033.

Exploring Antisense and RNAi Therapeutics Market

RNA therapeutics is the term for the application of oligonucleotides to target ribonucleic acids (RNA) primarily for therapeutic purposes or in investigations to clarify gene functions. The antisense and RNAi therapeutics market is supported by our expanding knowledge of RNA activities and their critical roles in disease. A number of RNA-based drugs are presently undergoing preclinical testing or inquiry before being licensed for clinical usage. Despite the enormous obstacles in producing therapies based on RNA, a variety of approaches have been investigated to improve RNA intracellular trafficking and metabolic stability.

From 2025 to 2030, the global antisense and RNAi therapeutics market is expected to see around US$ 7.38 billion in 2025 to reach about US$ 17.81 billion by 2030, with a strong annual growth rate of 19.12%. This surge is largely driven by increased investment in research for rare diseases, highlighting the growing demand for advanced genetic therapies.

How AI can Improve the Antisense and RNAi Therapeutics Market?

Large volumes of information on disease-associated RNAs and small molecules that bind to these RNAs have already been gathered as a result of the strategy's recent surge in popularity. By increasing the effectiveness and caliber of decision-making, artificial intelligence (AI) techniques such as machine learning and deep learning offer a chance to expedite the identification of RNA-targeted small molecules.

For instance,

• In December 2023, in order to anticipate the structure and function of ribonucleic acid (RNA), the US-based biotech startup Atomic AI has unveiled ATOM-1, a proprietary platform component that represents a large language model (LLM) that makes use of chemical mapping data. The model aims to tackle the difficulties related to creating RNA-based treatments.

Top Companies in the Antisense and RNAi Therapeutics Market

• GSK plc
• Deep Genomics
• Percheron Therapeutics Limited
• Sanofi
• Silence Therapeutics
• Exsilio Therapeutics
• Benitec Biopharma Inc.
• Arbutus Biopharma
• Ionis Pharmaceuticals, Inc
• Alnylam Pharmaceuticals, Inc.
• Olix Pharmaceuticals, Inc.
• Sarepta Therapeutics

Recent Development by Deep Genomics in the Antisense and RNAi Therapeutics Market

Recent Development by Exsilio Therapeutics in the Antisense and RNAi Therapeutics Market

Advancements in RNA Therapies Transform Rare Disease Treatment

The emergence of disease-modifying medications has given rise to new hopes as several nucleic acid (NA)-based therapies are now moving into the clinical stage. The era of NA-based therapies has completely changed the landscape of RD treatment. Genetic abnormalities and malignancies are among the many diseases for which RNA-based therapies have been extensively used.

For instance,

• According to data accessible from the Indian Council of Medical Research (ICMR), 9,675 people have joined the National Registry for Rare and Other Inherited Disorders (NRROID) portal since November 2019. Of these patients, 4,408 are from hospitals under central government control. The National Policy for Rare Diseases (NPRD), 2021, has set aside Rs. 92.84 Crore for the treatment of patients with rare diseases in the approved Centers of Excellence for the fiscal year 2023–2024.
• In the past, rare diseases were seen as medical oddities with little bearing on public health. Even though each of these illnesses is uncommon, 25 to 30 million Americans are thought to be afflicted. Over 3,000 applications have been assessed by UDP, and approximately 900 patients have been admitted to the NIH Clinical Center for thorough, week-long evaluations. Nearly 10,000 questions have also been received.

RNA Stability Issues Restraint the Antisense and RNAi Therapeutics Market

Notwithstanding their benefits, stability, and delivery remain critical factors in the future growth of therapeutic modalities. Because RNase in the cells or tissues can quickly break down RNA molecules due to their inherent instability, RNA molecules must be transported to the cytoplasm of the cell in order for them to govern biological activities within the cell. It is challenging for them to pass through the hydrophobic cytoplasmic membrane, though, because they are negative charges.

RNA-based drug Development is the Future of Antisense and RNAi Therapeutics Market

The recent invention of various RNA-based medications demonstrates the enormous promise of this topic. It is anticipated that novel RNA-based medications may surface to treat a range of illnesses for which there is now no known cure, based on the knowledge that has been gathered thus far. Drugs based on RNA have the ability to modify targets that were previously undruggable. Rapid medication design by researchers is another benefit of RNA treatment.

Report Highlights

Technology Insights

The antisense RNA segment held the largest share of the antisense and RNAi therapeutics market in 2023. One way to mute genes and prevent their expression is through antisense RNA (asRNA) technology. Replication, transcription, and translation are only a few of the stages at which antisense RNAs control the expression of genes. Furthermore, host cells' expression of linked genes can be efficiently controlled by synthetic antisense RNAs. As antisense RNA has evolved, a popular area of study has been centered on figuring out what roles these molecules play.

For instance,

• In May 2024, Isarna Therapeutics, a German company, is developing a range of antisense treatments that target transforming growth factor beta (TGF-B) signaling, a new therapeutic area in human biology. Antisense therapy, which precisely modulates TGF-B pathways, may lead to safer and more effective treatment alternatives for various diseases.

The RNA interference segment is anticipated to grow at the fastest rate in the antisense and RNAi therapeutics market during the forecast period. When it comes to treating a variety of pathologic disorders like cancer, viral infections, and cardiovascular diseases, RNA interference (RNAi) is thought to be a very selective method of gene silencing. The research of RNA interference has advanced quickly, moving from an experimental technique to a potent tool for developing new therapeutics.

Application Insights

The neurodegenerative disorders segment dominated the antisense and RNAi therapeutics market in 2023. The majority of neurodegenerative diseases affect the elderly population and are frequently fatal. Thus, one of the main areas of interest for biomedical research is therapeutic development. The potential to target more disease-associated genes through a range of diverse mechanisms grows with the number of RNA-based techniques.

For instance,

• According to the WHO, more than 60% of the world's 55 million dementia patients reside in low- and middle-income nations. Approximately 10 million new cases are reported annually. Numerous conditions and traumas to the brain can lead to dementia. The most prevalent type of dementia, accounting for 60–70% of cases, is Alzheimer's disease.

The genetic disorders segment is expected to grow with the fastest CAGR in the antisense and RNAi therapeutics market during the forecast period. Two amazing and intriguing developments in the field of modern biomedicine are RNA vaccines and RNA therapeutic applications. Treating genetic illnesses with gene therapy using the novel RNA editing method appears promising. Through RNA correction of the illness-causing mutation, UC San Diego researchers demonstrated in a proof of concept that the method can treat a mouse model of Hurler syndrome, a rare genetic disorder.

For instance,

• Rare diseases are, by definition, rare, affecting less than 1 in 2000 people in any given WHO region. Nevertheless, the global burden of rare diseases is not negligible, with over 7000 different forms of the disease. Currently, 300 million people worldwide suffer from uncommon diseases. Nearly 70% of rare diseases occur in childhood, and approximately 95% of them have no known cure. Approximately 80% of uncommon diseases have a genetic basis.

Route of Administration Insights

The intrathecal injections segment held the largest share of the antisense and RNAi therapeutics market in 2023. When using intrathecal drug delivery instead of oral or parenteral administration, far smaller quantities of medication are required to induce effective analgesia and decrease spasticity. Despite being an invasive process, intrathecal drug delivery system implantation has a low likelihood of complications. Intracerecal medication delivery has been extensively shown to be safe and effective in managing spasticity as well as pain associated with cancer and non-cancer conditions.

The subcutaneous injection segment is estimated to grow at the fastest rate in the antisense and RNAi therapeutics market during 2024-2033. Subcutaneous delivery carries fewer risks and is more convenient for patients when compared to intravenous (IV) administration. Additionally, because it is so simple to use, fewer medical personnel are required, which lowers healthcare costs. By avoiding first-pass extraction, which reduces interindividual variability and increases the amount of the medication available in the systemic circulation, oral administration also has an additional benefit.

Regional Insights

North America dominated the antisense and RNAi therapeutics market by 62.10% in 2023. The accessibility of cutting-edge antisense and RNAi treatments is one factor driving the market's expansion in the area. Additionally, the region's well-established healthcare infrastructure contributes to a rise in early rare illness screening, which in turn raises the demand for RNAi and antisense therapies. For example, Cure SMA is a nonprofit organization whose goal is to advance and fund spinal muscular atrophy research.

Furthermore, an environment that is favorable for research and the advanced development needed to advance antisense and RNAi therapy platforms has been established thanks to the extraordinary assistance of numerous national governments and other global health organizations. The existence of numerous top biotech and pharmaceutical businesses in the area has hastened development prospects and product launches, according to the antisense & RNAi therapies market analysis. This has fostered tough rivalry and promoted innovation. The market for RNA-based medicines is further supported by the proactive regulatory climate in North America and the extraordinary involvement of the FDA, which has accelerated the development of numerous RNA-based medications for a variety of hereditary and chronic illness disorders. Furthermore, there is a need for antisense and RNAi therapies due to the high prevalence of target diseases, such as cancer and genetic abnormalities, in the area.

For instance,

• In an effort to learn more about the unrealized potential of ribonucleic acid (RNA) for potentially extensive biotechnology applications, ranging from cancer-fighting treatments to crop disease prevention, the U.S. National Science Foundation has awarded nearly $12.7 million to nine research teams. The National Science Foundation (NSF) and the National Human Genome Research Institute (NHGRI) are collaborating to offer the nine teams $1 million to $1.65 million each through the Molecular Foundations for Biotechnology (MFB) program. In order to further explore RNA biology, NHGRI intends to fund new initiatives that will be revealed later in 2024 and center on the creation of innovative technologies.

Asia Pacific is expected to grow at the fastest rate during the forecast period. The main reason for the Asia Pacific antisense and RNAi therapeutics market's growth is that nations like China, Japan, and India are fostering domestic innovation and rapidly advancing their capacities for producing generic medications. A number of domestic biotech businesses are researching therapeutic treatments through RNA interference (RNAi) technologies. The comparatively reduced production costs in comparison to Western markets enable these players to concentrate on offering medications at reasonable prices. Owing to this benefit, multinational pharmaceutical companies are making major financial investments to increase their market share in various locations.

Recent Developments in the Antisense and RNAi Therapeutics Market

• In June 2023, the innovative AntiClasticTM Antisense Oligonucleotide (AntiClastic ASO) platform, developed by Alloy Therapeutics, a biotechnology ecosystem firm, has been made available. AntiClastic ASO uses ideally designed spatial conformation nucleic acids to further improve antisense's drug-like qualities. IP underpinning the AntiClastic ASO technology has been licensed exclusively to Alloy by Arnay Sciences LLC, owned by Sudhir Agrawal.
• In March 2023, after raising $52 million in funding, Switch Therapeutics, a preclinical stage biotechnology firm that is developing a novel approach to using RNA science to cure diseases, announced its launch. With additional funding from both new and existing investors, including Eli Lilly and Company, Ono Venture Investment, Digitalis Ventures, Dolby Family Ventures, Free Flow Ventures, PhiFund Ventures, and others, the company's Series A was co-led by Insight Partners and UCB Ventures.

Segments Covered in the Report

By Technology

• RNA Interference
• Antisense RNA

By Application

• Genetic Disease
• Cancer
• Infectious Disease
• Neurodegenerative Disorders
• Cardiometabolic & Renal Disorders
• Ocular Disorders
• Respiratory Disorders
• Skin Disorders

By Route of Administration

• Intravenous Injections
• Intrathecal Injections
• Subcutaneous Injections
• Other Delivery Methods

By Region

• North America 
  
  • U.S.
  • Canada
• Europe 
  
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific 
  
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Latin America 
  
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA) 
  
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait

Relevant Report

Strategic Insights: The Critical Role of Antibodies in Advancing Life Science Research and Diagnostics

Antibodies have become essential tools in life science research due to their precision in labeling and detection. In diagnostic medicine, these molecular markers enhance the accuracy of identifying specific antigens, allowing researchers to pinpoint the presence and concentration of particular proteins, which aids in diagnosing various diseases. Their high selectivity and specificity make them invaluable across biomedical research, including medicine, diagnostics, oncology, gene therapy, stem cell analysis, autoimmune disease therapy, and more.

The global research antibodies market size valued at approximately US$ 1.60 billion in 2023, is anticipated to reach US$ 2.55 billion by 2033. This growth represents a compound annual growth rate (CAGR) of 4.90% from 2024 to 2033. The increasing demand for high-quality antibodies to ensure reproducible research results is a key driver behind this market expansion.